IP Library Granted Patent US 10,905,763
Granted Patent B2
US 10,905,763 · App. 15/510,443 · Granted Feb 2, 2021

Compositions and methods for treatment of pre-cancerous skin lesions

Inventors: Lynn Cornelius (St. Louis, MO); Shadmehr Demehri (St. Louis, MO); Raphael Kopan (St. Louis, MO)
A61K45/06A61K31/513A61K31/59A61K31/593C07D243/04A61K2300/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,905,763
App. No.
15/510,443
Granted
Feb 2, 2021
Kind
B2
Abstract

The present disclosure encompasses compositions and methods for the treatment of precancerous skin lesions. Compositions of the invention comprise a cytotoxic agent and a thymic stromal lymphopoietin (TSLP) inducer.

Claims (7)

1. A method to treat actinic keratosis in a subject in need thereof, the method comprising topically administering to the subject a composition comprising about 2% to about 5% (wt/wt) 5-fluorouracil (5-FU) and a thymic stromal lymphopoietin (TSLP) inducer, wherein the TSLP inducer is about 0.002% to about 0.005% (wt/wt) calcipotriol.

2. The method of claim 1 , wherein the composition is administered twice a day for 4 to 6 days.

3. A method to prevent the transition of a precancerous skin lesion to skin cancer in a subject in need thereof, the method comprising:

a) identifying a subject with one or more precancerous skin lesion(s); and

b) topically administering to the precancerous skin lesion(s) a composition comprising about 2% to about 5% (wt/wt) 5-fluorouracil (5-FU) and a thymic stromal lymphopoietin (TSLP) inducer, wherein the TSLP inducer is about 0.002% to about 0.005% (wt/wt) calcipotriol.

4. The method of claim 3 , wherein the precancerous skin lesion is actinic keratosis and the skin cancer is squamous cell carcinoma.

5. The method of claim 3 , wherein the composition is administered twice a day for 4 to 6 days.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2017
From: CORNELIUS, LYNN ANNE, MD; DEMEHRI, SHADMEHR; KOPAN, RAPHAEL, PHD
To: WASHINGTON UNIVERSITY
Reel/Frame 041968/0107 →
CONFIRMATORY LICENSE Recorded Apr 3, 2017
From: WASHINGTON UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 042134/0469 →
Continuity (2)
Provisional Application 62048586 · Sep 10, 2014
Related Publication 20170246299A1 · Aug 31, 2017
Cited By (1)
US 12,186,394